ArticleOncotarget2017
Phenotypic characterization of circulating tumor cells in triple negative breast cancer patients.
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 33 citations in OpenAlex.
- Actionability of HER2-amplified circulating tumor cells in HER2-negative metastatic breast cancer: the CirCe T-DM1 trial.Breast cancer research : BCR · 2019Trial
- Liquid biopsy in TNBC: significance in diagnostics, prediction, and treatment monitoring.Frontiers in oncology · 2025Review
- Article
- Article
- Immunotherapy in patients with brain metastasis: advances and challenges for the treatment and the application of circulating biomarkers.Frontiers in immunology · 2023Review
- Liquid biopsies to occult brain metastasis.Molecular cancer · 2022Review
- Single HER2-positive tumor cells are detected in initially HER2-negative breast carcinomas using the DEPArray™-HER2-FISH workflow.Breast cancer (Tokyo, Japan) · 2022Article
- PARP-1 Expression andCancers · 2022Article
- Better together: circulating tumor cell clustering in metastatic cancer.Trends in cancer · 2021Review
- Dynamic changes of CTCs in patients with metastatic HR(+)/HER2(-) breast cancer receiving salvage treatment with everolimus/exemestane.Cancer chemotherapy and pharmacology · 2021Observational
- Liquid biopsies and cancer omics.Cell death discovery · 2020Review
- Review
- Molecular characterization of circulating tumour cells identifies predictive markers for outcome in primary, triple-negative breast cancer patients.Journal of cellular and molecular medicine · 2020Article
- Looking for a Better Characterization of Triple-Negative Breast Cancer by Means of Circulating Tumor Cells.Journal of clinical medicine · 2020Article
- Circulating Tumor Cells in Metastatic Breast Cancer: From Genome Instability to Metastasis.Frontiers in molecular biosciences · 2020Review
- The identification of a TNBC liver metastasis gene signature by sequential CTC-xenograft modeling.Molecular oncology · 2019Article
- The prognostic value of JUNB-positive CTCs in metastatic breast cancer: from bioinformatics to phenotypic characterization.Breast cancer research : BCR · 2019Article
- HER2 in stemness and epithelial-mesenchymal plasticity of breast cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2019Review
- Evaluation of α-tubulin, detyrosinated α-tubulin, and vimentin in CTCs: identification of the interaction between CTCs and blood cells through cytoskeletal elements.Breast cancer research : BCR · 2018Article
- Detection of HER2 Amplification in Circulating Tumor Cells of HER2-Negative Gastric Cancer Patients.Targeted oncology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPatients with triple negative breast cancer (TNBC), are considered as a poor prognosis group for whom no targeted therapies are currently available. The aim of the present study was to phenotypically characterize their CTCs in order to explore potential therapeutic targets.
methodsPBMC's cytospins were prepared from 45 early (before and after adjuvant chemotherapy), 10 metastatic TNBC and 21 hormone receptor (HR) -positive patients. The expression of Cytokeratins (CK), ER, PR, EGFR and HER2 on CTCs was assessed using immunofluoresence staining and ARIOL analysis.
resultsIn early stage TNBC, ER, PR, HER2 and EGFR expressing-CTCs were detected in 24.4%, 24.4%, 20% and 40% of patients before the initiation of adjuvant chemotherapy, and in 17.8%, 13.3% 6.7% and 51.1% respectively after the completion of adjuvant treatment. Triple staining experiments revealed distinct subpopulations of CTC expressed HR, and ErbB family receptors. In patients with metastatic disease, the frequency of HER2+ CTCs was significantly increased compared to adjuvant setting (60% vs 20%, p=0.014). The presence of CK+PR- CTCs, before adjuvant treatment was associated with reduced OS (p=0.032) and DFI (p=0.04). Furthermore, the frequency of ER-, PR- and HER2+ CTCs was higher in HR(+) than in TNBC tumors (57.1%, p=0.006; 52.4%, p=0.021 and 52.38%, p=0.009, respectively).
conclusionsThe CTCs in patients with early TNBC are phenotypically heterogeneous based on the expression of HR, EGFR and HER2 both before and after the completion of adjuvant chemotherapy whereas the presence of HER2+ CTCs prevails during disease evolution. These findings could be of clinical relevance in terms of CTC targeting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.